Prof. Andrés Ferreri | ICML 2017 | Extranodal Marginal Zone Lymphoma and the use of clarithromycin

Prof. Andrés Ferreri, from the San Raffaele Scientific Institute, Milan, IT, on the use of clarithromycin in Extranodal Marginal Zone Lymphoma:

Extranodal Marginal Zone Lymphoma and the use of clarithromycin

FDA approves rituximab-pvvr (Ruxience®), a rituximab biosimilar, for the treatment of patients with CD20-positive NHL and CLL

On 23 July 2019, the FDA approved rituximab-pvvr (Ruxience®), a monoclonal antibody biosimilar to rituximab, for multiple...

FDA approves rituximab-pvvr (Ruxience®), a rituximab biosimilar, for the treatment of patients with CD20-positive NHL and CLL

On 23 July 2019, the FDA approved rituximab-pvvr (Ruxience®), a monoclonal...

EHA 2019 | AUGMENT study: Post-hoc analysis in MZL

Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, shares a post-hoc analysis from AUGMENT study in marginal zone lymphoma (MZL).

EHA 2019 | AUGMENT study: Post-hoc analysis in MZL

Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, shares a post-hoc analysis from AUGMENT study in marginal zone lymphoma (MZL).

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox